Chinese pharmaceutical company Sinopharm announced that one million people received experimental ‘emergency’ vaccinations through the country’s national emergency program Wednesday.

"Our vaccines have been given to about one million people and we have not received any information about serious negative reactions," said Sinopharm’s Chairman, Liu Jingzhen.

Essential workers and other groups vulnerable to the virus have been included in the program, which was launched in July, with three COVID-19 vaccine candidates.

According to Reuters, two vaccine candidates were developed by Sinopharm’s subsidiary China National Biotech Group (CNBG) and the third vaccine was developed by Sinovac Biotech.

Sinopharm has yet to comment which vaccines were used in the emergency program and Jingzhen was unclear about which vaccine he was addressing.

The state company has yet to provide any clinical evidence of efficacy. However, no adverse reactions have been reported by the state, the company or the trial participants, said Sinopharm.

The Sinopharm vaccine requires two doses per individual for efficacy. The vaccine is currently undergoing a three phase clinical trial overseas with 60,000 participants. 40,000 participants have had blood samples taken upon being administered the second dose, said Jingzhen.

The third phase of the clinical trials is taking place in about 10 countries, including the United Arab Emirates, Argentina, Peru, Egypt and Jordan.

Sinopharm claims individuals who were vaccinated have since collectively traveled to over 150 countries and have yet to be infected.

However, experts have warned against the vaccine due to a lack of standard control from any clinical trial group. The data from an emergency program is inefficient and unable to determine a vaccine’s effectiveness.